Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2010
09/07/2010US7790713 Inhibitors of interleukin-1β converting enzyme
09/07/2010US7790703 New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability
09/07/2010US7790700 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
09/07/2010US7790698 2-Alkoxyadeosine or 2-alkoxy-3'-deoxyadenosine where the alkoxy contains 1-4 carbon atoms; particularly 2-methoxy-adenosine (spongosine) or salt; antiinflammatory agents; side effect reduction, particularly, cardiovascular disorders such as bradycardia and tachycardia
09/07/2010US7790674 Treating inflammatory disease; use in combination with other antiinflammatory agents such as anakinra; rheumatoid arthritis for example; Ang-2 inhibitor peptides of amino acid sequence WDPWT
09/07/2010US7790376 PREFERENTIAL CLASSIFICATON BETWEEN CANCER CELLS; OBTAIN SAMPLE, MONITOR SAMPLE FOR PREFERENTIAL ENZYMATIC ACTIVITY, EVALUATE DIFFERENTIATED CELLS; for of detecting presence or absence or level of a polynucleotide sequence encoding heparanase in a biological sample
09/07/2010US7790168 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
09/07/2010US7790165 Immunoglobulin specific to receptor protein DR5 for treatment of cancer, inflammatory or autoimmune diseases
09/07/2010US7790157 Methods of modulating CARK protein activity
09/07/2010US7790154 DNA viral plasmid for use as gene transfer tool in genetic engineering and genic therapy; improved exogenous transcriptional expression
09/07/2010US7790152 Monoclonal antibodies that preferntially bind to proteins having cytolysis and immunogenic activity
09/07/2010CA2608864C Recombinant mva virus, and the use thereof
09/07/2010CA2582452C Pegylated liposomal doxorubicin in combination with ecteinascidin 743
09/07/2010CA2493680C Condensed heterocyclic pyrazole derivatives as kinase inhibitors
09/07/2010CA2431188C Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
09/07/2010CA2405724C Substance p analogs for the treatment of cancer
09/07/2010CA2368676C Sphingomyelin containing preparation
09/07/2010CA2334615C Production process for polymeric micelle charged therein with drug and polymeric micelle composition
09/05/2010CA2665771A1 Method and kit for effecting screening and immunogenic treatment using crt and/or erp57 translocation
09/02/2010WO2010099536A2 Engineered proteins with high affinity for dota chelates
09/02/2010WO2010099526A1 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
09/02/2010WO2010099515A2 Apparatus, system, and method for creating immunologically enhanced spaces in-vivo
09/02/2010WO2010099472A2 Spanx-b polypeptides and their use
09/02/2010WO2010099445A2 Non-covalent inhibition of the 26s proteasome and uses thereof
09/02/2010WO2010099379A1 Jak kinase modulating quinazoline derivatives and methods of use thereof
09/02/2010WO2010099213A1 Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
09/02/2010WO2010099139A2 Combination anti-cancer therapy
09/02/2010WO2010099003A2 Compositions and methods for visualizing and eliminating cancer stem cells
09/02/2010WO2010098866A1 Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
09/02/2010WO2010098682A1 Cell marker for melanocyte lineage and cancer cells and uses thereof
09/02/2010WO2010098652A1 Cola nitida ( cola nut ) as an anticancer agent
09/02/2010WO2010098627A2 Pharmaceutical preparation
09/02/2010WO2010098613A2 Tm7sf3 composition for diagnosing liver cancer, diagnostic kit containing anti-tm7sf3 antibodies, and pharmaceutical composition for preventing or treating liver cancer
09/02/2010WO2010098429A1 Immunologic adjuvant composition and use thereof
09/02/2010WO2010098367A1 Pyrimidopyrimidoindazole derivative
09/02/2010WO2010098344A1 Tricyclic pyrazolopyrimidine derivative
09/02/2010WO2010098298A1 Pharmaceutical composition comprising combination of compound having nutrient digestion/absorption inhibitory activity and cyclohexanecarboxamide derivative
09/02/2010WO2010098265A1 Polymeric micelle containing proteasome inhibitor
09/02/2010WO2010098166A1 Cell adhesion inhibitor and use thereof
09/02/2010WO2010097798A1 6-phenyl-2-[((piperidin-4-ylmethyl)-piperazin-1yl) or piperazin 1-ylmethyl)-piperidin-1-yl)]-imidazo[2,1-b][1,3,4]thiadiazole derivatives and their use
09/02/2010WO2010097720A1 Use of a fragment of rasgap peptide in the treatment or prevention of metastasis
09/02/2010WO2010097641A1 SIGMA(σ) RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTICANCER ACTIVITY
09/02/2010WO2010097419A1 Conditionally replicating adenovirus effective in the treatment of tumors
09/02/2010WO2010097334A1 Drug combinations containing pde4 inhibitors and nsaids
09/02/2010WO2010097332A1 Drug combinations containing pde4 inhibitors and nsaids
09/02/2010WO2010097248A1 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
09/02/2010WO2010096853A1 Methods of modulating the activity of the mc1 receptor and treatment of conditions related to this receptor
09/02/2010WO2010068037A9 Anti-cancer composition containing 4-hexylresorcinol-1,3-diol as active ingredient
09/02/2010WO2010064172A3 Isolated compounds from phaleria macrocarpa as anti-cancer agents
09/02/2010WO2010063138A8 A monoclonal antibody specifically binding to vegf and the hybridoma secreting same and uses thereof
09/02/2010WO2010057028A9 Treatment of proteinopathies using a farnesyl transferase inhibitor
09/02/2010WO2010047509A9 Anti-dr5 antibody with improved affinity and stability, and composition for cancer prevention or treatment including same
09/02/2010WO2010045469A3 Muc18 targeting peptides
09/02/2010WO2010028066A3 Cd133 epitopes
09/02/2010WO2009139921A3 Microorganisms for preventing and treating neoplasms accompanying cellular therapy
09/02/2010WO2009131712A3 Regulatory b cells and their uses
09/02/2010WO2009094426A8 13,13-dimethyl-des-c,d analogs of 1alpha, 25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof
09/02/2010WO2007022041A3 Mutations and polymorphisms of hdac3
09/02/2010US20100223680 Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
09/02/2010US20100222437 Composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases
09/02/2010US20100222436 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
09/02/2010US20100222424 Method of Screening Drug with the Use of 67 kDa Laminin Receptor and Drug Obtained Thereby
09/02/2010US20100222419 Method to inhibit cell growth using oligonucleotides
09/02/2010US20100222418 Combination Products For Treating Cancer
09/02/2010US20100222416 Diagnostic Marker and Therapeutic Target for Cancer
09/02/2010US20100222411 Vhz for diagnosis and treatment of cancer
09/02/2010US20100222407 Triblock copolymers for cytoplasmic delivery of gene-based drugs
09/02/2010US20100222406 T Type Calcium Channel Blockers and the Treatment of Diseases
09/02/2010US20100222400 F1F0-ATPase Inhibitors and Related Methods
09/02/2010US20100222382 Esters of Compounds in the Leptomycin Family
09/02/2010US20100222381 Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
09/02/2010US20100222380 Modified Chalcone Compounds as Antimitotic Agents
09/02/2010US20100222379 Novel histone deacetylase inhibitors
09/02/2010US20100222371 Prevention of surgical adhesions
09/02/2010US20100222370 Methods of Treating Cancer
09/02/2010US20100222367 Pyrazine kinase inhibitors
09/02/2010US20100222366 Piperidine derivatives as modulators of chemokine receptor activity
09/02/2010US20100222364 Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia
09/02/2010US20100222362 N-oxides of n-phenyl-2-pyramidine-amine derivatives
09/02/2010US20100222360 Treatment of Malignant Peripheral Nerve Sheath Tumors
09/02/2010US20100222356 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents
09/02/2010US20100222352 Compounds and Methods for the Treatment of Viruses and Cancer
09/02/2010US20100222348 Quinolinone derivatives as parp inhibitors
09/02/2010US20100222344 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
09/02/2010US20100222343 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
09/02/2010US20100222342 Pyrrolopyrazole, potent kinase inhibitors
09/02/2010US20100222341 Piperidine and piperazine derivatives
09/02/2010US20100222332 Pyrazolo-pyrazines derivatives used as g protein inhibitors
09/02/2010US20100222331 New compounds
09/02/2010US20100222326 New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
09/02/2010US20100222321 Inhibitors of akt activtiy
09/02/2010US20100222319 Nicotinamide derivatives, preparation thereof and therapeutic use thereof
09/02/2010US20100222311 Solid formulations of crystalline compounds
09/02/2010US20100222306 Class of Gamma Delta T Cells Activators and Use Thereof
09/02/2010US20100222300 A2B Adenosine Receptor Antagonists
09/02/2010US20100222299 Compound
09/02/2010US20100222294 Formulations of ATP and Analogs of ATP
09/02/2010US20100222292 Method for transdifferentiation of body tissues
09/02/2010US20100222287 Therapeutic Cancer Treatments
09/02/2010US20100222286 Receptor modulators exhibiting neuroprotective and memory enhancing activities
1 ... 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 ... 2211